Press Release

Visiongain Ltd.

Antisense and RNAi Therapeutics Market Report 2021 to 2031 By Visiongain

April 6th, 2021 12:00 AM

Visiongain has published a new report on Antisense and RNAi Therapeutics Market Report to 2031. According to the Visiongain analysis, the global Antisense and RNAi Therapeutics market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global Antisense and RNAi Therapeutics market is segmented by technology (RNA Interference, Antisense RNA), by application (Oncology, Cardiovascular Diseases (CVDs), Infectious Diseases, Genetic Disorders, Others), by administration (Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Others). By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Antisense and RNAi Therapeutics Companies. PLUSCOVID-19 Recovery Scenarios.

Global Antisense and RNAi Therapeutics Market was valued at US$XX billion in 2021 and is projected to reach a market value of US$ XX billion by 2031.

Download a Sample Report with Table of Contents and Figures by clicking here: @

COVID-19 Impact on the Global Antisense and RNAi Therapeutics Market
The COVID-19 pandemic is caused due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2. The need to develop significant and effective therapeutics is increasing. However, the innate RNA interference (RNAi) mechanism enables to develop front line therapies to prevent from virus. Through specific binding approach and therapeutic targets by using short interfering RNA (siRNA) and short hairpin RNA (shRNA) molecules. However, Pfizer Inc. and BioNTech SE submitted amended protocol to the U.S. Food and Drug Administration to enhance phase-3 pivotal COVID-19 vaccine trial. The companies are collaborating to combat & develop COVID-19 vaccine, BNT162 mRNA vaccine program, and modRNA candidate BNT162b2.

Market Driver
Technological advancements and innovation
Various molecular technologies are intended to regulate gene expression, are developed recently as strategy to combat inflammatory and neoplastic diseases. The antisense technology has rapid, specific, significant approach to inhibit gene expression through recognition of cellular RNAs. However, the advancement in human genome sequencing, rational design of oligonucleotides, theoretical easiness, and affordable costs of compounds led to use them as therapeutic agents or tools to assess gene function.

Request your free report overview by emailing: @

Increasing collaborations among bio-pharmaceutical companies

In October 2018, Arrowhead pharmaceutics entered into a license agreement with Janssen Pharmaceuticals, Inc., (Johnson & Johnson) to develop and commercialize ARO-HBV. In April 2019, the company presented clinical data from an ongoing Phase 1/2 study (AROHBV1001) of JNJ-3989 (formerly ARO-HBV). The RNAi therapeutic are considered as the potential treatment for patients with chronic hepatitis B virus infection. It was presented at the International Liver Congress2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL). However, the increasing collaboration among the companies are boosts the global antisense & RNAi therapeutics market.

Market Opportunity

Rising approval &drug launch of RNA therapeutics plays significant role in the growth of the market.
The European Medicines Agency has suggested approval for Alnylam’s Givlaari (givosiran) for acute hepatic porphyria (AHP). The (RNAi) drug is approved in European Union and the United States to treat AHP, which is rare and life-threatening genetic condition. The ONPATTRO (patisiran) received US FDA approval for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (HATTR) in adults. The increasing approval & regular product launches for the antisense & RNAi therapeutics further creates opportunity for the market.

To request a overview of this report please contacts Sara Peerun at or refer to our website: @

Competitive Landscape
Tekmira Pharmaceuticals, Ionis Pharmaceuticals, Glaxo Smith Kline, Alnylam Pharmaceuticals Inc., Antisense Therapeutics, Sanofi-Genzyme, Silence Therapeutics, F. Hoffmann-La Roche Ltd, Sirnaomics Inc., Gene Signal, BioNTech, Quark Pharmaceuticals, CureVac AGare some of the key players contributing to the growth of the global Antisense and RNAi Therapeutics market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.

In April 2018, Arbutus Biopharma Ltd with Roivant launched Genevant Sciences, which enables in discovery, development, and commercialization of RNA-based therapeutics. The company received licensed exclusive rights to its LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of Hepatitis B virus.

In August 2020, Alnylam Pharmaceutics Inc. received United States Food and Drug Administration (FDA) approval of an RNAi Therapeutic, ONPATTRO (patisiran), to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis (HATTR) in adults. The approval enables to treat hATTR amyloidosis, which is rare, inherited, life-threatening disease. The hATTR amyloidosis may lead to other significant disabilities such as decreased ambulation with the loss of the ability to walk unaided, a reduced quality of life, and a decline in cardiac functioning.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

Find more research reports on pharma industry, by Visiongain:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market research and consulting company in Europe. Based in London, UK, the company comprises over 400+ analysts and consultants, adding more than 1400 market research reports to its vast database each year. These reports offer in-depth analysis on 18 industries worldwide. With the help of an interactive market intelligence platform, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Sara Peerun
Commercial Director
Visiongain Limited
Phone: +44 (0) 20 7549 9987.

Report Source:
Press Release Source:


Follow us

LinkedIn | Facebook | Twitter

Press Release

  • Recent
  • Popular
  • Comments
  • Cryotherapy Industry Growth Prospect, Future Trend, Comprehensive Analysis and Forecasts 2021 to 2026

    Learn More
  • Malaria Vaccines Industry 2021 In-depth Industry Analysis By Types, Applications

    Learn More
  • Scaffold Technology Industry 2026 : Detailed survey of the key competitors and the leading players

    Learn More
  • Healthcare IT Industry 2021 Global Industry Trends, Statistics, Competition Strategies, Revenue Analysis, Key Players

    Learn More
  • IBM Watson Services Market 2021-2028: Industry Analysis and Forecast

    Learn More
  • Lithium-Ion Battery Cathode Market Regional Analysis, Competitive Landscape and Forecast to 2028

    Learn More
  • Cell Banking Outsourcing Industry Opportunities Future Guidelines Value Chain Forecast To 2025

    Learn More
  • Visiongain Publishes Directed Energy Weapons (DEW) Market Report 2021-2031

    Learn More